Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tolerx, Inc.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Like other comparative claims, say attorneys at the National Advertising Division’s annual conference, advertising that denigrates a competing brand must be substantiated. Advertising detailed previously in HBW Insight that compared nutritional products’ formulations and skin moisturizers’ effectiveness were noted as examples of denigrating claims.
“We selected Lumify based on its strong business performance in years one and two, and the success it had in growing a category through premiumization," says Nielsen’s BASES leader, Ben Macedo.
- Large Molecule